Cases & Deals

Celgene acquires Triphase Accelerator's first compound, Marizomib

Client(s) Celgene Corporation

Jones Day advised Celgene Corporation in the acquisition, through an affiliate, of Triphase Accelerator Corporation's assets related to its proteasome inhibitor, marizomib (MRZ), which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.

In addition to M&A representation, Jones Day provided health care, intellectual property, tax, and regulatory advice regarding this transaction.